Business Context and Reporting Period
P3 Health Partners Inc. (P3) is a patient-centered, physician-led population health management company operating primarily in the Medicare Advantage (MA) market. The company utilizes an at-risk, capitated model where it receives fixed monthly payments to manage the total healthcare needs of attributed members. This Form 10-Q covers the quarterly and six-month periods ended June 30, 2026.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Operating Revenue | $386,381 | $772,771 |
| Net Income (Loss) | $15,651 | $18,691 |
| Net Loss Attributable to Class A Common Stockholders | $(2,126) | $(903) |
| Adjusted EBITDA | $54,445 | $80,204 |
| Medical Margin (Non-GAAP) | $97,803 | $171,460 |
| Cash and Restricted Cash | $22,194 | $22,194 (Ending Balance) |
| Net Cash Used in Operating Activities | N/A | $(89,381) |
| Total Debt (Current + Long-Term) | $119,854 | $119,854 (Ending Balance) |
| Working Capital Deficit | $(209,243) | $(209,243) (Ending Balance) |
Material Changes vs. Prior Period
- Revenue Growth: Total operating revenue increased 9% year-over-year (YoY) for the quarter and 6% for the six-month period. This growth was driven by higher average rates due to contractual restructuring and risk adjustment improvements, despite a 10% decrease in average at-risk membership (from 115,900 to 104,800) due to strategic rationalization of underperforming contracts.
- Profitability: The company reported a net income of $15.7 million for the quarter, a significant improvement from a net loss of $43.7 million in the same period in 2025. However, after deducting cumulative preferred stock dividends of $9.6 million, the net loss attributable to Class A common stockholders was $2.1 million.
- Medical Expense Reduction: Medical expenses decreased 15% YoY for the quarter ($300.4 million vs. $351.4 million), driven by lower membership counts and a $36.2 million reduction in prior period medical claims expense.
- Debt Restructuring: On April 27, 2026, the company exchanged approximately $252.5 million of unsecured promissory notes (VGS 1-5) for cumulative preferred stock (Series A, B, and C). This transaction significantly reduced interest expense but introduced substantial cumulative dividend obligations.
- Non-GAAP Adjustments: Adjusted EBITDA improved to $54.4 million for the quarter from a loss of $17.1 million in the prior year, largely due to the reversal of premium deficiency reserves and improved medical margins.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for one year following the issuance of the financial statements. The company has a working capital deficit of $209.2 million and negative operating cash flows of $89.4 million for the six months ended June 30, 2026.
- Capital Raising: The company is actively exploring additional debt and equity financing. On April 27, 2026, it entered a Securities Purchase Agreement to issue up to $70 million of Series D Preferred Stock and warrants. As of June 30, $18.7 million remained available, with an additional $16 million sold on July 1, 2026.
- Preferred Stock Risks: The new preferred stock carries cumulative dividend rates between 13.5% and 19.5%. These dividends are senior to common stock and can be paid in-kind, leading to compounding obligations that reduce earnings available to common shareholders and increase liquidation preferences.
- Legal Proceedings: The company is cooperating with a Civil Investigative Demand (CID) from the U.S. Department of Justice regarding arrangements with insurance agents and brokers under the False Claims Act.
- Unusual Items: The financial results include a $16.4 million mark-to-market loss on stock warrants and purchased put options for the quarter. Additionally, a $6.4 million release of uncertain tax positions contributed to an income tax benefit for the six-month period.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $21.3 million unrestricted cash balance against the $209.2 million working capital deficit and ongoing negative operating cash flows.
- Preferred Stock Dilution: Assess the impact of the $308.4 million aggregate stated value of preferred stock and its compounding cumulative dividends on future earnings per share and liquidation value for common stockholders.
- Membership Trends: Confirm the sustainability of revenue growth given the 10% decline in at-risk membership and the reliance on rate increases rather than volume expansion.
- Debt Covenants: Review compliance with the Term Loan Facility covenants and the risk of default given the company's liquidity constraints.
- Regulatory Exposure: Monitor the outcome of the DOJ investigation regarding broker remuneration and potential fines or operational changes.